产品封面图

小鼠体内IFNG中和抗体,体外IFNG中和抗体

收藏
  • ¥5600
  • bioXCELL
  • 美国
  • BE0055-5MG
  • 2025年07月15日
    avatar
  • 企业认证

    点击 QQ 联系

    • 详细信息
    • 询价记录
    • 文献和实验
    • 技术资料
    • 克隆性

      多克隆

    • 抗体英文名

      InVivoMAb anti-mouse IFNγ

    • 抗体名

      体外IFNG中和抗体

    • 规格

      5mg

    小鼠体内IFNG中和抗体,体外IFNG中和抗体
    Bio X Cell抗体优势:
    ✔ 通过大规模的组织培养生产抗体,亲和层析法纯化抗体,
    ✔ 所有抗体均具有高纯度(>95%)、低内毒素(<2EU/mg),无防腐剂和稳定剂的特性,适用于体内临床前研究
    ✔ 所有抗体可提供100mg甚至50g的大包装,性价比非常高
    Bio X Cell抗体应用
    产品细节图片1
    热销抗体
    抗原 应用 克隆号 InVivoMab
    目录号
    InVivoPlus
    目录号
    PD-1 体内PD-1/PD-L1信号封闭 RMP1-14 BE0146 BP0146
    体内PD-1/PD-L1信号封闭,体外PD-1中和,IHC(冰冻),IF,WB,FC 29F.1A12 BE0273 BP0273
    体内PD-1/PD-L1信号封闭,体外PD-1中和,WB J43 BE0033-2 BP0033-2
    InVivo rat IgG2a isotype control, PD-1同型对照,排除Fc段与抗原的非特异性结合 2A3 BE0089 BP0089
    PD-L1(B7-H1) 体内PD-L1信号封闭,IF,IHC(冰冻),FC,WB 10F.9G2 BE0101 BP0101
    InVivo rat IgG2b isotype control, PD-L1同型对照,排除Fc段与抗原的非特异性结合 LTF-2 BE0090 BP0090
    CTLA-4 体内 CTLA-4 中和,WB 9D9 BE0164 BP0164
    体内和体外中和CTLA-4,WB 9H10 BE0131 BP0131
    体内和体外中和CTLA-4,FC,WB UC10-
    4F10-11
    BE0032 BP0032
    NK1.1 体内NK细胞去除,FC PK136 BE0036 BP0036
    CD3ε 体内T细胞去除,体外T细胞刺激/激活,IF,FC,WB, 145-2C11 BE0001-1 BP0001-1
    CD4 体内CD4+T细胞去除,FC,WB GK1.5 BE0003-1 BP0003-1
    CD8α 体内CD8+T细胞去除,IF,FC,WB 53-6.7 BE0004-1 BP0004-1
    CD25 (IL-2Rα) 体内调节T细胞去除,FC PC-61.5.3 BE0012 BP0012
    CD28 体内CD8封闭,体外T细胞刺激/激活 37.51 BE0015-1 /
    体外T细胞刺激/激活 PV-1 BE0015-5 /
    CSF1R (CD115) 体内巨噬细胞去除,体外CSF-R1中和,体内单核细胞去除, FC,WB AFS98 BE0213 BP0213
    IL-4 体内IL-4中和,体外IL-4中和,体内IL-4受体刺激(as a complex with IL-4)
    FC,WB
    11B11 BE0045 BP0045
    IFNγ (interferon
    gamma)
    体内IFNγ中和,体外IFNγ中和,ELISPOT,FC,WB XMG1.2 BE0055 BP0055
    Ly6G 体内中性粒细胞耗竭,体内MDSC耗尽, IF,IHC(石蜡或冰冻),FC 1A8 BE0075-1 BP0075-1
    Ly6G/Ly6C (Gr-1) 体内Gr-1+骨髓细胞去除,IHC(石蜡或冰冻),FC RB6-8C5 BE0075 BP0075
    IFNAR-1 体内IFNAR-1阻断,体外IFNAR-1阻断,WB MAR1-5A3 BE0241 BP0241
    InVivoMab VS InVivoPlus
    - InVivoMab InVivoPlus
    纯度 >95% >95%
    蛋白完整性 √(SDS-PAGE) √(SDS-PAGE)
    内毒素浓度 2EU/mg <1EU/mg
    有效性验证(WB/FC/ELISA)
    蛋白聚集物<5%
    小鼠病原体测试
    无叠氮化物和载体蛋白
    大批量生产
    适用体内研究
    目录号 BE开头 BP开头
    InVivoPlusTM 系列抗体非常适用于高灵敏性实验以及用活细胞或整个动物进行各种功能测定的体内研究,可加快您的研究进展。

    热销同型对照和InVivoPure抗体稀释Buffer
    产品类型 品名 用途 InVivoMab
    目录号
    InVivoPlus
    目录号
    部分热卖同型
    对照
    InVivoMab rat IgG2a isotype control 排除一抗的Fc段与
    抗原的非特异性结合,
    使实验结果更加严谨,
    有助于您发表高分论文
    BE0089 BP0089
    InVivoMab rat IgG2b isotype control BE0090 BP0090
    InVivoMab mouse IgG1 isotype control BE0083 BP0083
    InVivoMAb human IgG1 isotype control BE0297 BP0297
    InVivoPlus rat IgG2a isotype control BE0089 BP0089
    InVivoMab mouse IgG2a isotype control BE0085 BP0085
    InVivoMabrat IgG1 isotype control BE0088 BP0088
    InVivoPlus mouse IgG1 isotype control BE0083 BP0083
    InVivoMAb polyclonal Armenian hamster IgG BE0091 BP0091
    抗体稀释Buffer InVivoPure pH 7.0 Dilution Buffer 官方指定抗体稀释
    buffer,确保抗体使用
    性能,加快您的实验进展
    IP0070 /
    InVivoPure pH 6.5 Dilution Buffer IP0065 /
    ✔ 为了加快您实验进度,确保实验结果的准确性,建议您搭配使用Bio X Cell一抗对应的同型对照(排除一抗的非特异性结合)和InVivoPure抗体稀释缓冲液。

    About InVivoMAb anti-mouse IFNγ

    The XMG1.2 monoclonal antibody reacts with mouse IFNγ (interferon gamma) a 20 kDa soluble pleiotropic cytokine and the sole member of the type II class of interferons. IFNγ is primarily produced by activated lymphocytes including T, B, NK cells, and ILCs. IFNγ exerts immunoregulatory, anti-proliferative, anti-viral, and proinflammatory activities and plays an important role in activation, growth, and differentiation of T and B lymphocytes, macrophages, NK cells and other non-hematopoietic cell types. Additionally, IFNγ induces the production of cytokines, Fc receptor, and adhesion molecules and up-regulates MHC class I and II antigen expression by antigen presenting cells during an immune response. IFNγ has also been shown to modulate macrophage effector functions, influence isotype switching and induce the secretion of immunoglobulins by B cells. IFNγ signals through the IFN gamma receptor which exists as a heterodimer composed of CD119 (IFN gamma receptor 1) and AF-1 (IFN gamma receptor 2). The IFNγ receptor is expressed ubiquitously on almost all cell types with the exception of mature erythrocytes. The XMG1.2 antibody is a neutralizing antibody.

    InVivoMAb anti-mouse IFNγ Specifications

    Isotype Rat IgG1, κ
    Recommended Isotype Control(s) InVivoMAb rat IgG1 isotype control, anti-horseradish peroxidase(BE0088)
    Recommended InVivoPure Dilution Buffer InVivoPure pH 8.0T Dilution Buffer(IPT080)
    Immunogen Recombinant mouse IFNγ
    Reported Applications
    • in vivo IFNγ neutralization
    • in vitro IFNγ neutralization
    • ELISPOT
    • Flow cytometry
    • Western blot
    Endotoxin
    • <2EU/mg (<0.002EU/μg)
    • Determined by LAL gel clotting assay
    Purity
    • >95%
    • Determined by SDS-PAE
    Formulation
    • PBS + 0.01% Tween, pH 8.0
    • Contains no stabilizers or preservatives
    Sterility 0.2 μM filtered
    Production Purified from tissue culture supernatant in an animal free facility
    Purification Protein G
    Storage The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
    RRID AB_1107694
    Molecular Weight 150 kDa

    Application References

    InVivoMAb anti-mouse IFN (Clone: XMG1.2)

    Glasner, A., et al. (2018). "NKp46 Receptor-Mediated Interferon-gamma Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis." Immunity 48(1): 107-119 e104. PubMed Natural killer (NK) cells are innate lymphoid cells, and their presence within human tumors correlates with better prognosis. However, the mechanisms by which NK cells control tumors in vivo are unclear. Here, we used reflectance confocal microscopy (RCM) imaging in humans and in mice to visualize tumor architecture in vivo. We demonstrated that signaling via the NK cell receptor NKp46 (human) and Ncr1 (mouse) induced interferon-gamma (IFN-gamma) secretion from intratumoral NK cells. NKp46- and Ncr1-mediated IFN-gamma production led to the increased expression of the extracellular matrix protein fibronectin 1 (FN1) in the tumors, which altered primary tumor architecture and resulted in decreased metastases formation. Injection of IFN-gamma into tumor-bearing mice or transgenic overexpression of Ncr1 in NK cells in mice resulted in decreased metastasis formation. Thus, we have defined a mechanism of NK cell-mediated control of metastases in vivo that may help develop NK cell-dependent cancer therapies. Clever, D., et al. (2016). "Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche." Cell 166(5): 1117-1131 e1114. PubMed Cancer cells must evade immune responses at distant sites to establish metastases. The lung is a frequent site for metastasis. We hypothesized that lung-specific immunoregulatory mechanisms create an immunologically permissive environment for tumor colonization. We found that T-cell-intrinsic expression of the oxygen-sensing prolyl-hydroxylase (PHD) proteins is required to maintain local tolerance against innocuous antigens in the lung but powerfully licenses colonization by circulating tumor cells. PHD proteins limit pulmonary type helper (Th)-1 responses, promote CD4(+)-regulatory T (Treg) cell induction, and restrain CD8(+) T cell effector function. Tumor colonization is accompanied by PHD-protein-dependent induction of pulmonary Treg cells and suppression of IFN-gamma-dependent tumor clearance. T-cell-intrinsic deletion or pharmacological inhibition of PHD proteins limits tumor colonization of the lung and improves the efficacy of adoptive cell transfer immunotherapy. Collectively, PHD proteins function in T cells to coordinate distinct immunoregulatory programs within the lung that are permissive to cancer metastasis. Cao, A. T., et al. (2015). "Interleukin (IL)-21 promotes intestinal IgA response to microbiota." Mucosal Immunol 8(5): 1072-1082. PubMed Commensal microbiota-specific T helper type 17 (Th17) cells are enriched in the intestines, which can convert into T follicular helper (Tfh) in Peyer's patches, and are crucial for production of intestinal immunoglobulin A (IgA) against microbiota; however, the role of Th17 and Tfh cytokines in regulating the mucosal IgA response to enteric microbiota is still not completely known. In this study, we found that intestinal IgA was impaired in mice deficient in interleukin (IL)-17 or IL-21 signaling. IL-21, but not IL-17, is able to augment B-cell differentiation to IgA(+) cells as mediated by transforming growth factor beta1 (TGFbeta1) and accelerate IgA class switch recombination (CSR). IL-21 and retinoic acid (RA) induce IgA(+) B-cell development and IgA production and drives autocrine TGFbeta1 production to initiate IgA CSR. Repletion of T-cell-deficient TCRbetaxdelta(-/-) mice with Th17 cells specific for commensal bacterial antigen increased the levels of IgA(+) B cells and IgA production in the intestine, which was blocked by neutralizing IL-21. Thus IL-21 functions to strongly augment IgA production under intestinal environment. Furthermore, IL-21 promotes intestinal B-cell homing through alpha4beta7 expression, alone or with TGFbeta and RA. Together, IL-21 from microbiota-specific Th17 and/or Tfh cells contributes to robust intestinal IgA levels by enhancing IgA(+) CSR, IgA production and B-cell trafficking into the intestine. Choi, Y. S., et al. (2015). "LEF-1 and TCF-1 orchestrate TFH differentiation by regulating differentiation circuits upstream of the transcriptional repressor Bcl6." Nat Immunol 16(9): 980-990. PubMed Follicular helper T cells (TFH cells) are specialized effector CD4(+) T cells that help B cells develop germinal centers (GCs) and memory. However, the transcription factors that regulate the differentiation of TFH cells remain incompletely understood. Here we report that selective loss of Lef1 or Tcf7 (which encode the transcription factor LEF-1 or TCF-1, respectively) resulted in TFH cell defects, while deletion of both Lef1 and Tcf7 severely impaired the differentiation of TFH cells and the formation of GCs. Forced expression of LEF-1 enhanced TFH differentiation. LEF-1 and TCF-1 coordinated such differentiation by two general mechanisms. First, they established the responsiveness of naive CD4(+) T cells to TFH cell signals. Second, they promoted early TFH differentiation via the multipronged approach of sustaining expression of the cytokine receptors IL-6Ralpha and gp130, enhancing expression of the costimulatory receptor ICOS and promoting expression of the transcriptional repressor Bcl6.

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    • 作者
    • 内容
    • 询问日期
    图标文献和实验
    相关实验
    • AAV 在肝脏研究中的应用策略

      在肝脏中应用较多的有 AAV1、AAV2、AAV3、AAV5、AAV8 及 AAV-DJ 等血清型:   Mouse:AAV8、AAV-DJ 对 mouse 肝脏均具有较强的亲嗜性,其中 AAV8 嗜肝性更强,用于活体动物注射表现为免疫原性低, 感染效率高;AAV-DJ 的体内肝细胞转导效率与 AAV8 相近,且在体外实验中也能表现出较强的感染效率。   Rat:AAV1、AAV2 对 rat 肝脏均具有较强的亲嗜性,AAV8 并不推荐,因为感染效率并不优秀。   注意事项: ① 小鼠的品系

    • 新冠病毒及变异株疫苗新突破:环状 RNA 疫苗

      病毒刺突蛋白(Spike)受体结构域(RBD)的环状 RNA 疫苗。 实验证明,该疫苗可以在小鼠和恒河猴体内诱导产生高水平的新冠病毒中和抗体以及特异性 T 细胞免疫反应,并可以有效降低新冠病毒感染的恒河猴肺部的病毒载量,显著缓解新冠病毒感染引起的肺炎症状。 CircRNA 疫苗接种在小鼠和恒河猴体内提供了显著性保护 二、环状 RNA 疫苗的优势 一系列的对比评估表明,与 mRNA 疫苗相比,circRNA 疫苗具有以下特点或优势: 1)circRNA 具有更高的稳定性,可以在体内

    • 中科院高福院士课题组 2020 年发表了哪些重要的研究成果?

      在肿瘤细胞同时表达https://doi.org/10.1073/pnas.19214451172020 年 3 月 24 日,高福院士联合高山等在 PNAS 发文:Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy。研究显示 PD-1 在广泛的肿瘤细胞中表达。PD-1 或其配体 PD-L1 的沉默可促进体外细胞增殖和集落形成以及体内肿瘤

    图标技术资料

    暂无技术资料 索取技术资料

    小鼠体内IFNG中和抗体,体外IFNG中和抗体
    ¥5600